GLYXAMBI (empagliflozin and linagliptin tablets)
Glyxambi is used to lower blood sugar levels in patients with type 2 diabetes mellitus. Glyxambi may be used when diet plus exercise do not provide adequate blood sugar level control either: alone or with certain other medicines for diabetes such as metformin.
Home | (empagliflozin and linagliptin tablets)
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Overseas Patient/ Export inquires.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
GLYXAMBI (empagliflozin and linagliptin tablets)
Empagliflozin and linagliptin combination is used together with proper diet and exercise to treat high blood sugar levels caused by type 2 diabetes. It is also used to lower the risk of death in patients with type 2 diabetes and heart or blood vessel disease.
GLYXAMBI is a prescription medicine that contains 2 diabetes medicines, empagliflozin (JARDIANCE) and linagliptin (TRADJENTA). GLYXAMBI can be used:
o along with diet and exercise to lower blood sugar in adults with type 2 diabetes,
o in adults with type 2 diabetes who have known cardiovascular disease when empagliflozin (JARDIANCE), one of the medicines in GLYXAMBI, is needed to reduce the risk of cardiovascular death.
GLYXAMBI is not for people with type 1 diabetes. It may increase their risk of diabetic ketoacidosis (increased ketones in blood or urine).
If you have had pancreatitis in the past, it is not known if you have a higher chance of getting pancreatitis while you take GLYXAMBI.
GLYXAMBI is not for use to lower blood sugar in adults with type 2 diabetes who have severe kidney problems, because it may not work.
It is not known if GLYXAMBI is safe and effective in children.
Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It is a combination of empagliflozin and linagliptin.It was approved for use in the United States in January 2015, for use in the European Union in November 2016, and for use in Australia in December 2016.
Drug (Brand / Generic): GLYXAMBI / empagliflozin and linagliptin tablets
Current Indications: 2 diabetes
Marketed by:: Boehringer Ingelheim Pharmaceuticals.
Approval Date: 2015
Available as (Form & Strength): Tablets
10 mg empagliflozin/5 mg linagliptin
25 mg empagliflozin/5 mg linagliptin
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier / importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “GLYXAMBI (empagliflozin and linagliptin tablets)”.
Confirmation of the order for GLYXAMBI (empagliflozin and linagliptin tablets) will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand GLYXAMBI (empagliflozin and linagliptin tablets). The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to GLYXAMBI (empagliflozin and linagliptin tablets), they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
Kindly reach out to us for GLYXAMBI (empagliflozin and linagliptin tablets) price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.